AA
AKBA icon

ALPS Advisors’s Akebia Therapeutics AKBA Stock Holding History

ALPS Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Buy
272,262
+54,192
+25% +$64.5K ﹤0.01% 1080
2026
Q1 		$303K Buy
218,070
+179
+0.1% +$246 ﹤0.01% 976
2025
Q4 		$351K Buy
217,891
+91,830
+73% +$192K ﹤0.01% 924
2025
Q3 		$344K Sell
126,061
-15,603
-11% -$51.9K ﹤0.01% 940
2025
Q2 		$516K Buy
+141,664
New +$389K ﹤0.01% 627
2019
Q2 		– Sell
-282,329
Closed -$2.31M – 879
2019
Q1 		$2.31M Buy
282,329
+61,934
+28% +$425K 0.02% 209
2018
Q4 		$1.22M Buy
220,395
+119,447
+118% +$935K 0.01% 266
2018
Q3 		$891K Buy
100,948
+18,399
+22% +$165K 0.01% 434
2018
Q2 		$824K Buy
82,549
+19,151
+30% +$192K 0.01% 380
2018
Q1 		$604K Buy
63,398
+11,019
+21% +$154K ﹤0.01% 420
2017
Q4 		$779K Buy
52,379
+6,007
+13% +$99.6K 0.01% 308
2017
Q3 		$912K Buy
46,372
+11,323
+32% +$174K 0.01% 258
2017
Q2 		$504K Buy
35,049
+2,079
+6% +$26.4K ﹤0.01% 485
2017
Q1 		$303K Sell
32,970
-3,860
-10% -$37.7K ﹤0.01% 689
2016
Q4 		$383K Sell
36,830
-11,630
-24% -$100K ﹤0.01% 619
2016
Q3 		$439K Sell
48,460
-4,890
-9% -$41.6K ﹤0.01% 368
2016
Q2 		$399K Buy
53,350
+10,728
+25% +$93.6K ﹤0.01% 459
2016
Q1 		$384K Buy
42,622
+2,270
+6% +$18.4K ﹤0.01% 569
2015
Q4 		$521K Sell
40,352
-4,785
-11% -$48.8K 0.01% 388
2015
Q3 		$436K Buy
45,137
+16,533
+58% +$152K ﹤0.01% 603
2015
Q2 		$294K Buy
28,604
+18,563
+185% +$158K ﹤0.01% 658
2015
Q1 		$112K Buy
+10,041
New +$107K ﹤0.01% 654

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ALPS Advisors's AKBA Position: Q2 2026 in Review

ALPS Advisors increased its Akebia Therapeutics (AKBA) stake by 25% in Q2 2026, buying an estimated $64.5K and bringing the position to 272,262 shares worth $310K. The position accounts for ﹤0.01% of the portfolio, ranked #1080.

ALPS Advisors first reported a position in AKBA in Q1 2015 and has held it in 22 quarters since. The position peaked at $2.31M in Q1 2019. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • ALPS Advisors held 272,262 shares of Akebia Therapeutics worth $310K as of Q2 2026.
  • ALPS Advisors bought 54,192 Akebia Therapeutics shares in Q2 2026, an estimated $64.5K.
  • Akebia Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1080 holding.
  • ALPS Advisors first reported a position in Akebia Therapeutics in Q1 2015 and has held it in 22 quarters since.
  • ALPS Advisors's Akebia Therapeutics position peaked at $2.31M in Q1 2019.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.